Millennium Initiates Pivotal Phase III Clinical Trial Comparing VELCADE (Bortezomib) for Injection With High-Dose Dexamethasone in Patients With Multiple Myeloma
- Topics:
- Healthcare Services
- Source:
- Millennium Pharmaceuticals
FREE Registration is required
Overview: In this article Millennium Pharmaceuticals, Inc. discusses the initiation of a pivotal phase III clinical trial of VELCADE (formerly known as MLN341, LDP-341 and PS-341) in patients with multiple myeloma, the second most common hematologic cancer. The company also announced they have filed the trade name VELCADE, for trademark registration, and will use VELCADE as the naming convention for MLN341. The trade name will be subject to approval by the FDA and other regulatory authorities during the NDA/MAA submission and approval process.
(Is this item miscategorized? Does it need more tags? Let us know.)
Format: HTML | Date: Jun 2002 | Pages: 3
People who downloaded this item also downloaded
 |
FDA Approves VELCADE (Bortezomib) for Injection for the Treatment of Relapsed and Refractory Multiple Myeloma |
